A Comparative Study on the Clinical Efficacy and Safety between Combination Therapy with CDK 4/6 Inhibitor and AI Versus AI Monotherapy in HR+/HER type2- Advanced Breast Cancer: Updated Meta-analysis
Author:
Affiliation:
1. College of Pharmacy, Kyungsung University, Busan 48434, Republic of Korea
2. Ulsan University Hospital, Ulsan 682-714, Republic of Korea
Funder
National Research Foundation
Publisher
The Korean College of Clinical Pharmacy
Subject
General Medicine
Link
http://pdf.medrang.co.kr/KJCP/2020/030/KJCP030-01-01.pdf
Reference29 articles.
1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
2. National Cancer Institute. SEER Cancer Stat Facts :Female Breast Cancer. Available from <uri>https://seer.cancer.gov/statfacts/html/breast.html</uri>. Accessed May 2, 2019.
3. Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2015, Ministry of Health and Welfare, 2017. Available from <uri>http://ncc.re.kr/cancerStatsList.ncc?searchKey=total&searchValue=&pageNum=1</uri>. Accessed May 2, 2019.
4. Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
5. Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3